Abstract
Aim and Objectives: The aim of the study was to compare the efficacy of Atenolol and Olmesartan in Stage-1 hypertension (HTN), and the adverse effect profile of Atenolol and Olmesartan in Stage-1 HTN. Methods: A prospective, randomized, open, and parallel study was carried out in 100 patients attending the outpatient department of General Medicine Department MMIMSR, Mullana, Ambala, India with Stage -1 HTN according to joint national committee VII. The patients were randomly divided into two groups to receive Tab. Atenolol 50 mg od (Group A, n=50) and Tab. Olmesartan medoxomil 20 mg (Group B, n=50) od for a total period of 12 weeks with regular follow up every 2 weeks from the baseline. At each visit, blood pressure (BP), heart rate, and adverse effects were evaluated. Laboratory investigations were carried out at baseline and end of the study period. p<0.005 was considered statistically significant. Results: Atenolol and Olmesartan medoxomil both significantly reduce BP and heart rate (p<0.005). Olmesartan medoxomil is more efficacious in reducing BP. Conclusion: Olmesartan medoxomil is a better choice for Stage -1 HTN between the two drugs as it leads to a greater decrement in BP.
Highlights
Cardiovascular disease (CVD) is one of the most common contributors of morbidity and mortality in underdeveloped and developing countries including South Asian countries including India [1]
The results of the blood pressure (BP) of individual patients were consolidated at the end of 12 weeks after treatment for both groups
When we compared the results of these studies, we found that a reduction of 20.7 mmHg of systolic BP (SBP) was observed in the Van Miegham study, while a reduction of 19.24 mmHg was observed in our study, and results are almost coinciding with each other [69]
Summary
Cardiovascular disease (CVD) is one of the most common contributors of morbidity and mortality in underdeveloped and developing countries including South Asian countries including India [1]. Among the cluster group of CVDs, hypertension (HTN) represents the most common form of cardiovascular risk factor [3]. The prevalence of HTN increases with advancing age [5]. It affects approximately onethird of the world’s adult population and it is predicted to increase by 60% toward 2025 [6]. The JNC 8 classification for HTN and guideline management algorithm has been recently released in 2014 [13]. Several risk factors have been identified for the development of Primary or Essential HTN [16,17]. Inadequate intake of potassium, calcium, and magnesium has been implicated in the risk of HTN in various populations study but not in all trials [19,20]. Lowering BP in patients with HTN significantly decreased cardiovascular morbidity and mortality as compared with a
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Pharmaceutical and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
